SCT-I10A + SCT200

SCT-I10A + SCT200 is a combination therapy consisting of two monoclonal antibodies. SCT-I10A targets programmed cell death 1 (PD-1), an immune checkpoint protein, while SCT200 targets the epidermal growth factor receptor (EGFR). This dual-targeted approach aims to enhance the immune system's ability to attack cancer cells by blocking both EGFR-mediated tumor growth and PD-1-mediated immune suppression. The combination has shown promising efficacy and safety in patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) who have exhausted standard treatment options, with notable objective response rates and disease control rates[1][3][5].